GlassScriptPhysician profile
Msalam M Sara
NPI 1760773931
$7,141.55
in general payments reported to CMS, 2019-2025
24 companies · $994 in 2025
The $994 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931 · 2020: $1,104 · 2021: $1,385 · 2022: $1,196 · 2023: $725 · 2024: $806 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.21 |
| Education | $330.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,585.69 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,328.36 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $1,319.12 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Mylan Specialty L.P. | $590.14 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $522.00 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $348.61 | 2019-2025 | |
| Medtronic Vascular, INC. | $238.81 | 2019-2020 | |
| Abbott Laboratories | $208.54 | 2021-2022 | |
| Viatris Specialty LLC | $142.87 | 2025 | Yupelri |
| Medtronic, INC. | $138.30 | 2021 | |
| Genzyme Corporation | $117.76 | 2021-2025 | |
| Insmed, INC. | $102.64 | 2025 | Arikayce, Brinsupri |
| Intuitive Surgical, INC. | $94.58 | 2023 | Da Vinci Surgical System |
| Edwards Lifesciences Corporation | $90.39 | 2024 | Hemosphere |
| Sanofi-Aventis U.S. LLC | $66.99 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $59.42 | 2019-2022 | |
| Verona Pharma, INC. | $38.99 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $30.05 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.60 | 2022 | |
| Genentech USA, INC. | $21.30 | 2019 | |
| Allergan, INC. | $20.25 | 2019 | |
| Octapharma USA, INC. | $19.29 | 2025 | Balfaxar |
| Bardy Diagnostics, INC. | $17.16 | 2021 | |
| Amgen INC. | $15.69 | 2024 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Msalam Sara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.